Folate receptor alpha ( FRα / FOLR1 ) and HER2 immunohistochemical staining in high‐grade endometrial carcinoma with aberrant p53 expression

Ähnliche Einträge

• Prognostic performance of FIGO 2023 endometrial carcinoma staging: a comparison to FIGO 2009 staging in the setting of known and unknown molecular classification
  von: Diane Libert, et al.
  Veröffentlicht: (2024)
• Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low‐ and high‐stage tumours
  von: Austin McHenry, et al.
  Veröffentlicht: (2024)
• The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile
  von: Mona Alafraidi, et al.
  Veröffentlicht: (2024)
• SOX17 expression in mesonephric‐like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Müllerian biomarker
  von: Xiaoming Zhang, et al.
  Veröffentlicht: (2024)
• Correlation between P53 immunohistochemical staining and TP53 molecular testing in endometrial carcinomas: a detailed assessment of discrepant cases with implications for patient management
  von: Jesús Machuca‐Aguado, et al.
  Veröffentlicht: (2025)